WT2725 / Sumitomo Pharma - LARVOL DELTA

Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies. (ASCO 2017) - P1; "One of the seven subjects with ≥1 year survival had previous treatment with bevacizumab. Preliminary data suggests WT2725 is well tolerated with potential antitumor activity in GBM patients, supporting future development of WT2725 for treatment of GBM in selected subjects."

Clinical • P1 data • Acute Myelogenous Leukemia • Biosimilar • Non Small Cell Lung Cancer • Ovarian Cancer • Renal Cell Carcinoma

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. (PubMed, Sci Rep) - P1 | "WT2725 dosing emulsion was well tolerated. Preliminary tumor response and biological marker data suggest that WT2725 dosing emulsion may exert antitumor activity in malignancies known to overexpress the WT1 protein, particularly glioblastoma, and provide a rationale for future clinical development.Trial registration: NCT01621542."

Clinical • Journal • P1 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • Wilms Tumor • WT1